Cover Image
市場調查報告書

視神經炎:開發平台分析

Optic Neuritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251578
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
視神經炎:開發平台分析 Optic Neuritis - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 56 Pages
簡介

視神經是從眼睛傳達視覺情報到大腦的神經纖維束,這些神經發炎就稱為視神經炎,會伴隨有疼痛、失明、閃光等。危險因子有年老、遺傳變異、性別等。

本報告提供視神經炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

視神經炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Biogen Idec Inc.
  • Bionure Farma, S.L.
  • Mallinckrodt plc
  • Meta-IQ ApS
  • 田邊三菱製藥
  • Neuralstem, Inc.
  • TEIJIN FIBERS製藥

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BIIB-033
  • BN-201
  • corticotropin
  • etomoxir
  • fingolimod hydrochloride
  • immune globulin (human)
  • NSI-566

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8614IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis - Pipeline Review, H2 2016, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.

Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff's phenomenon and flashing lights. Risk factors include age and genetic mutations.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Optic Neuritis.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Optic Neuritis Overview
  • Therapeutics Development
    • Pipeline Products for Optic Neuritis - Overview
    • Pipeline Products for Optic Neuritis - Comparative Analysis
  • Optic Neuritis - Therapeutics under Development by Companies
  • Optic Neuritis - Therapeutics under Investigation by Universities/Institutes
  • Optic Neuritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Optic Neuritis - Products under Development by Companies
  • Optic Neuritis - Products under Investigation by Universities/Institutes
  • Optic Neuritis - Companies Involved in Therapeutics Development
    • Biogen Inc
    • Bionure Farma, S.L.
    • Commence Bio, Inc.
    • Lipocure Ltd.
    • Meta-IQ ApS
    • Neuralstem, Inc.
    • Teijin Limited
  • Optic Neuritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etomoxir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gypenoside - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methylprednisolone sodium phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • opicinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Optic Neuritis - Dormant Projects
  • Optic Neuritis - Discontinued Products
  • Optic Neuritis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 01, 2015: Biogen Presents Phase 2 Data On Anti-LINGO-1 at ECTRIMS Congress
      • Apr 14, 2015: Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
      • Jan 08, 2015: Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Optic Neuritis, H2 2016
  • Number of Products under Development for Optic Neuritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Optic Neuritis - Pipeline by Biogen Inc, H2 2016
  • Optic Neuritis - Pipeline by Bionure Farma, S.L., H2 2016
  • Optic Neuritis - Pipeline by Commence Bio, Inc., H2 2016
  • Optic Neuritis - Pipeline by Lipocure Ltd., H2 2016
  • Optic Neuritis - Pipeline by Meta-IQ ApS, H2 2016
  • Optic Neuritis - Pipeline by Neuralstem, Inc., H2 2016
  • Optic Neuritis - Pipeline by Teijin Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Optic Neuritis - Dormant Projects, H2 2016
  • Optic Neuritis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Optic Neuritis, H2 2016
  • Number of Products under Development for Optic Neuritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top